Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Axxam S.p.A.
BioCentury | Dec 9, 2023
Discovery & Translation
Blood signature of organ aging; plus updates from Roche, Feldan, Rezo
BioCentury’s roundup of translational innovations
BioCentury | Jan 23, 2021
Emerging Company Profile
Technology showcase: BioCentury’s 2020 class of emerging companies
A snapshot of the next iteration of gene and cell therapies, gene editors, protein degraders and more
BioCentury | Sep 24, 2020
Emerging Company Profile
Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels
Libra aims at altered autophagy, neurotoxic protein production pathways shared across neurodegenerative disorders
BioCentury | May 11, 2015
Product Development
Check your effectors
Phase Ib data suggest Kineta's Kv1.3 blocker may quell autoimmune flares
Items per page:
1 - 10 of 19